Revue du rhumatisme (Ed. française : 1993)
-
The facet syndrome seems to be a common cause of low back pain. Percutaneous radiofrequency lumbar facet denervation, developed by Shealy, may be of therapeutic value in facet syndrome patients. This method consists in thermocoagulation of the middle branch of the dorsal primary ramus of the spinal nerve. ⋯ Success rates reported in the literature vary widely, from 14% to 76%. Interpretation of these data is difficult since studies used a broad range of treatment techniques, evaluation methods, and patient selection criteria. A prospective study using stringent inclusion criteria and appropriate evaluation criteria taking quality of life into account is needed to determine the role of percutaneous facet denervation among other treatment options available to low back pain patients.
-
Facet syndrome is an apparently common although not readily identifiable cause of low back pain. To evaluate the efficacy of corticosteroid facet joint injection for the treatment of low back pain, we retrospectively studied 206 patients with low back pain ascribed to facet syndrome. Effectiveness was evaluated on the basis of a clinical score and of a questionnaire completed 10 to 34 months after treatment. ⋯ These broad ranges denote substantial variations in evaluation criteria and patient selection. Only two placebo-controlled trials have been performed. There is a need for a prospective study with strict inclusion criteria and appropriate evaluation criteria taking quality of life into account to determine the role of facet joint injection in low back pain.
-
A patient with systemic lupus erythematosus developed unexplained fever, nonregenerative anemia, leukopenia, and elevations in serum triglyceride and ferritin levels. Bone marrow studies established the diagnosis of macrophage activation syndrome with active hemophagocytosis. No infectious cause was found but pulmonary nocardiosis developed during the course of the disease. ⋯ Investigations for an underlying infection are often negative, suggesting that the macrophage activation syndrome is due to lupus-related immune changes. Treatment is not standardized and relapses are common. This diagnosis should be considered in lupus patients with febrile pancytopenia.